1-氯-9h-2,4,9-三氮杂芴 | 98792-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 1-氯-9h-2,4,9-三氮杂芴
• 中文别名: 1-氯-9H-2,4,9-三氮杂-芴
• 英文名称: 4-chloro-5H-pyrimido[5,4-b]indole
• CAS: 98792-02-0
• 化学式: C₁₀H₆ClN₃
• mdl: MFCD00457089
• 分子量: 203.631
• InChiKey: RDAAOOPSZHGKFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-氯-9h-2,4,9-三氮杂芴 在 sodium hydroxide 、 硫脲 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 (5H-Pyrimido[5,4-b]indol-4-ylsulfanyl)-acetic acid ethyl ester
  参考文献：
  名称：

  Synthesis and biological activity of condensed pyrrolo[3,2-d]pyrimidines

  摘要：

  DOI：

  10.1007/bf00766579
• 作为产物：
  描述：

  3-氨基-2-吲哚羧酸乙酯 在 三氯氧磷 作用下， 以 1,4-二氧六环 、 formamide 为溶剂， 反应 10.0h， 生成 1-氯-9h-2,4,9-三氮杂芴
  参考文献：
  名称：

  4-肼基-5 H-嘧啶基[5,4- b ]吲哚的合成及相关化合物

  摘要：

  本文描述了两种4-氨基-5-的合成ħ嘧啶并[5,4- b ]吲哚5，4-肼基-5- ħ嘧啶并[5,4- b ]吲哚6中，两个1,2,4-三唑并[4，3- c ]嘧啶[5，4- b ]吲哚8和四唑并[ 4，5- c ]嘧啶[5，4- b ]吲哚10。从3-氨基吲哚-2-羧酸乙酯1开始，通过与甲酰胺缩合获得5 H-嘧啶基[5,4 - b ]吲哚-4-酮2（80％）。2的反应用三氯氧化磷和五硫化二磷分别制得4-氯-5 H-嘧啶并[5,4- b ]吲哚3（70％）和5 H-嘧啶并[5,4- b ]吲哚并4-硫酮4（80 ％）。化合物3与胺（吗啉，哌啶）反应生成相应的4-氨基-5 H-嘧啶[5,4- b ]-吲哚5，化合物4与肼反应生成4-肼基-5 H-嘧啶[ 5,4- b ]吲哚6（80％）。两个6（亚苄基，异亚丙基）7也准备了（9​​0％）。化合物6与甲酸和乙酸反应生成（65-75％）各自的1,2

  DOI：

  10.1002/jhet.5570230302

文献信息

• Light-Emitting Element, Display Device, Electronic Device, and Lighting Device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US20170025615A1

  公开（公告）日：2017-01-26

  Provided is a light-emitting element including a first organic compound, a second organic compound, and a guest material. The LUMO level of the first organic compound is lower than that of the second organic compound. The HOMO level of the first organic compound is lower than that of the second organic compound. The LUMO level of the guest material is higher than that of the first organic compound. The HOMO level of the guest material is higher than that of the second organic compound. An energy difference between the LUMO level and the HOMO level of the guest material is larger than an energy difference between the LUMO level of the first organic compound and the HOMO level of the second organic compound. The guest material can convert triplet excitation energy into light emission. The combination of first organic compound and the second organic compound can form an exciplex.

  提供的是一个包括第一有机化合物、第二有机化合物和客体材料的发光元件。第一有机化合物的LUMO能级低于第二有机化合物的LUMO能级。第一有机化合物的HOMO能级低于第二有机化合物的HOMO能级。客体材料的LUMO能级高于第一有机化合物的LUMO能级。客体材料的HOMO能级高于第二有机化合物的HOMO能级。客体材料的LUMO能级和HOMO能级之间的能量差大于第一有机化合物的LUMO能级和第二有机化合物的HOMO能级之间的能量差。客体材料可以将三重激发能量转化为光发射。第一有机化合物和第二有机化合物的组合可以形成一个激基复合物。
• [EN] PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR)<br/>[FR] DERIVES PYRROLOPYRIMIDINIQUES CONVENANT COMME MODULATEURS DE LA MULTIRESISTANCE AUX MEDICAMENTS
  申请人：XENOVA LTD

  公开号：WO2004111052A1

  公开（公告）日：2004-12-23

  A compound which is a pyrrolopyrimidine of formula (I) wherein R1 is selected from H, Cl-C6 alkyl which is unsubstituted or substituted, (CH2)nAr1, (CH2)pNR4R5, halogen and (CH2)pX; R2 is CH2)pArl; R3 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)pZ and (CH2)pArl; P is an unsaturated 5, 6, or 7 membered carbocyclic or heterocyclic ring which is unsubstituted or substituted; R4 and R5 which are the same or different are selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)nC3-C10 cycloalkyl, (CH2)nAr1 , and (CH2)nOR6, or R4 and R5 together with the nitrogen atom to which they are attached, form a saturated five or six membered nitrogen containing heterocyclic ring which may contain one extra heteroatom selected from 0, N and S and which is unsubstituted or substituted; R6 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl, (CH2)nOC1-C6alkyl which is unsubstituted or substituted, (CH2)nO(CH2)nAr1 , (CH2)nCO2C1-C6,alkyl which is unsubstituted or substituted and (CH2)nAr1; X is selected from CN, azide, (CH2)nNHSO2R6 and (CH2)nNHCOR6; Z is selected from CN, CO2R6 and CONR4R5; Ar1 is the same or different when more than one is present within a given substituent group and is an unsaturated C6-C10 membered carbocylic group or an unsaturated 5-11 membered heterocycle, either of which is unsubstituted or substituted; p is an integer of 1 to 6; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of 1 to 6; with the proviso that the pyrrolepyrimidine compound of formula (I) is other than 1-(4-benzyl-piperazin-1-yl)-9H-2,4,9-triaza-fluorene; and the pharmaceutically acceptable salts thereof, have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

  化合物是一种公式为（I）的吡咯吡嘧啶，其中R1从H、未取代或取代的Cl-C6烷基、（CH2）nAr1、（CH2）pNR4R5、卤素和（CH2）pX中选择；R2为（CH2）pArl；R3从H、未取代或取代的Cl-C6烷基、（CH2）pZ和（CH2）pArl中选择；P为未取代或取代的不饱和5、6或7成员碳环或杂环；R4和R5相同或不同，从H、未取代或取代的Cl-C6烷基、（CH2）nC3-C10环烷基、（CH2）nAr1和（CH2）nOR6中选择，或者R4和R5与它们连接的氮原子一起形成饱和的含氮五元或六元杂环，可能含有一个额外的杂原子，选择自O、N和S，未取代或取代；R6从H、未取代或取代的Cl-C6烷基、C3-C10环烷基、（CH2）nOC1-C6烷基、未取代或取代的（CH2）nO（CH2）nAr1、未取代或取代的（CH2）nCO2C1-C6烷基和（CH2）nAr1中选择；X从CN、叠氮、（CH2）nNHSO2R6和（CH2）nNHCOR6中选择；Z从CN、CO2R6和CONR4R5中选择；Ar1当多个存在于给定的取代基组内时相同或不同，为未取代或取代的不饱和C6-C10成员碳环或未取代或取代的不饱和5-11成员杂环；p为1至6的整数；n当多个存在于给定的取代基组内时相同或不同，为0或1至6的整数；但是，公式（I）的吡咯吡嘧啶化合物不是1-（4-苄基哌嗪-1-基）-9H-2,4,9-三氮杂萘；其药学上可接受的盐具有作为MRP（多药耐药蛋白）抑制剂的活性，因此可用于调节多药耐药性，例如在增强化疗药物的细胞毒性方面。
• Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US20160293863A1

  公开（公告）日：2016-10-06

  As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency is provided. The organometallic complex includes a metal and a ligand. The metal is iridium or platinum. The ligand includes a 5H-pyrimido[5,4-b]indole skeleton and an aryl group bonded to the 4-position of the 5H-pyrimido[5,4-b]indole skeleton. The 3-position of the 5H-pyrimido[5,4-b]indole skeleton and the aryl group are bonded to the metal. In the formula, M represents iridium or platinum. In addition, Ar represents a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, and each of R 1 to R 6 independently represents hydrogen, a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 10 carbon atoms.

  作为具有新颖骨架的新型物质，提供了一种具有高发射效率的有机金属配合物。该有机金属配合物包括金属和配体。金属为铱或铂。配体包括5H-嘧啶并[5,4-b]吲哚骨架和连接到5H-嘧啶并[5,4-b]吲哚骨架的4位的芳基基团。5H-嘧啶并[5,4-b]吲哚骨架的3位和芳基基团与金属结合。在公式中，M代表铱或铂。此外，Ar代表具有6到13个碳原子的取代或未取代的芳基基团，每个R1到R6独立地代表氢，具有1到6个碳原子的取代或未取代的烷基基团，或具有6到10个碳原子的取代或未取代的芳基基团。
• Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
  申请人：Grotzfeld M. Robert

  公开号：US20050153989A1

  公开（公告）日：2005-07-14

  Described herein are compounds and compositions for modulating kinase activity, and methods for modulating kinase activity using the compounds and compositions. Also described herein are methods of using the compounds and/or compositions in the treatment and prevention of a variety of diseases and unwanted conditions in subjects.

  本文描述了用于调节激酶活性的化合物和组合物，以及使用这些化合物和组合物调节激酶活性的方法。本文还描述了在治疗和预防受试者中各种疾病和不良状况中使用这些化合物和/或组合物的方法。
• 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药 物的应用
  申请人：上海医药工业研究院

  公开号：CN104045642B

  公开（公告）日：2016-08-24

  本发明公开了一类含嘧啶或吡啶结构的稠环化合物及其作为抗肿瘤药物的应用，所述稠环化合物为具有如式（I）所示的化合物或其药学上可接受的盐；本发明的化合物，作为抗肿瘤药物应用时，具有更强的抗肿瘤活性和更小的毒副作用，更易于作为抗肿瘤药物使用。